title: Recent in vitro findings of negative inotropy of pantoprazole did not translate into clinically relevant effects on left ventricular function in healthy volunteers.
abstract: OBJECTIVE
  Reports on cardiac problems with oral proton pump inhibitors have caused extensive safety reviews by the US Food and Drug Administration. We provide additional data on acute cardiac effects of an intravenous application.
  
  
  METHODS
  Echocardiography was performed in 18 healthy volunteers after administration of a common high-dose regimen of pantoprazole (80 mg i.v. bolus followed by 8 mg/h for 1 h) or placebo.
  
  
  METHODS
  The design included a randomized, double-blind, placebo-controlled cross-over trial.
  
  
  RESULTS
  Ejection fraction (%, mean +/- SE) in the treatment group (placebo group) was 60.7 +/- 1.1 (61.2 +/- 1.7) at baseline, and 62.6 +/- 1.1 (62.1 +/- 1.9), 64.7 +/- 1.6 (63.5 +/- 1.3), 62.6 +/- 1.6 (61.0 +/- 1.6) and 63.0 +/- 1.4 (61.8 +/- 1.5) at 7.5, 15, 30 and 60 min after bolus application, respectively (p = n.s.). Similarly, no significant changes were found for cardiac output, cardiac index, blood pressure and heart rate. In contrast, gastric pH that was used as a treatment control was significantly increased 60 min after the application of pantoprazole as compared to baseline and to placebo.
  
  
  CONCLUSIONS
  Pantoprazole as injection is safe in healthy subjects with respect to cardiac contractile function. However, in view of recent reports of negative inotropy of the drug, further studies in heart failure patients are required.
authors.affiliation: Herzzentrum, Kardiologie und Pneumologie, Universitätsmedizin Göttingen, Germany. Wolfgang.Schillinger@medizin.uni-goettingen.de
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Schillinger
authors.forename: Nina
authors.initials: N
authors.lastname: Hörnes
authors.forename: Nils
authors.initials: N
authors.lastname: Teucher
authors.forename: Samuel
authors.initials: S
authors.lastname: Sossalla
authors.forename: Daniel
authors.initials: D
authors.lastname: Sehrt
authors.forename: Klaus
authors.initials: K
authors.lastname: Jung
authors.forename: Mark
authors.initials: M
authors.lastname: Hünlich
authors.forename: Bernhard
authors.initials: B
authors.lastname: Unsöld
authors.forename: Bianca
authors.initials: B
authors.lastname: Geiling
authors.forename: Giuliano
authors.initials: G
authors.lastname: Ramadori
authors.forename: Reinhard
authors.initials: R
authors.lastname: Hilgers
authors.forename: Harald
authors.initials: H
authors.lastname: Schwörer
authors.forename: Gerd
authors.initials: G
authors.lastname: Hasenfuss
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000009:adverse effects*; D000293:Adolescent; D000328:Adult; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D017506:H(+)-K(+)-Exchanging ATPase / Q000009:adverse effects; D006801:Humans; D008297:Male; D000077402:Pantoprazole; D015990:Placebo Effect; D016277:Ventricular Function, Left / Q000187:drug effects* / Q000502:physiology*; D055815:Young Adult
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000077402:Pantoprazole; D017506:H(+)-K(+)-Exchanging ATPase